Further studies reveal that HACE1 causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells by activating nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2) via multiple mechanisms. This evidence concerns the gene HACE1 and central nervous system cancer.